Switching p53-Dependent Growth Arrest To Apoptosis Via The Inhibition Of DNA Damage-Activated Kinases

Cellular and Molecular Biology Letters

Volumn 15, Issue 3, 2010, Pages 473-484

  Hublarova, Pavla ^a   Greplova, Kristina ^a   Holcakova, Jitka ^a   Vojtesek, Borivoj ^a   Hrstka, Roman ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

ATM ATR kinases; Chk2; Cisplatin; Doxorubicin; Inhibitors of DNA damage activated kinases; Protein p53

Indexed keywords

2 [4 (4 CHLOROPHENOXY)PHENYL] 1H BENZIMIDAZOLE 5 CARBOXAMIDE; ATM PROTEIN; ATR PROTEIN; CGK 733; CHECKPOINT KINASE 2; CISPLATIN; DOXORUBICIN; PROTEIN P53; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ATR PROTEIN, HUMAN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; GENE EXPRESSION; GROWTH INHIBITION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; TRANSACTIVATION; CELL CYCLE G0 PHASE; DRUG ANTAGONISM; FLOW CYTOMETRY; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DNA-BINDING PROTEINS; DOWN-REGULATION; DOXORUBICIN; FLOW CYTOMETRY; G0 PHASE; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 77956912169     PISSN: 14258153     EISSN: 16891392     Source Type: Journal    
DOI: 10.2478/s11658-010-0021-5     Document Type: Article

References (43)

1. Ko, L. J. and Prives, C. p53: puzzle and paradigm. Genes Dev. 10 (1996) 1054-1072.
2. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell88 (1997) 323-331.
3. Barak, Y., Juven, T., Haffner, R. and Oren, M. mdm2 expression is induced by wild type p53 activity. EMBO J. 12 (1993) 461-468.
4. Wu, X., Bayle, J. H., Olson, D. and Levine, A. J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7 (1993) 1126-1132.
5. Lane, D. P. Cancer. p53, guardian of the genome. Nature358 (1992) 15-16.
6. Saito, S., Goodarzi, A. A., Higashimoto, Y., Noda, Y., Lees-Miller, S. P., Appella, E. and Anderson, C. W. ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J. Biol. Chem. 277 (2002) 12491-12494.
7. Siliciano, J. D., Canman, C. E., Taya, Y., Sakaguchi, K., Appella, E. and Kastan, M. B. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 11 (1997) 3471-3481.
8. Bartek, J. and Lukas, J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 3 (2003) 421-429.
9. Fedier, A., Schlamminger, M., Schwarz, V. A., Haller, U., Howell, S. B. and Fink, D. Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites. Ann. Oncol. 14 (2003) 938-945.
10. Shiloh, Y. The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci. 31 (2006) 402-410.
11. Canman, C. E., Wolff, A. C., Chen, C. Y., Fornace, A. J., Jr. and Kastan, M. B. The p53-dependent G1 cell cycle checkpoint pathway and ataxiatelangiectasia. Cancer Res. 54 (1994) 5054-5058.
12. Canman, C. E., Lim, D. S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B. and Siliciano, J. D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science281 (1998) 1677-1679.
13. Banin, S., Moyal, L., Shieh, S., Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y. and Ziv, Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science281 (1998) 1674-1677.
14. Hirao, A., Kong, Y. Y., Matsuoka, S., Wakeham, A., Ruland, J., Yoshida, H., Liu, D., Elledge, S. J. and Mak, T. W. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science287 (2000) 1824-1827.
15. Lin, W. C., Lin, F. T. and Nevins, J. R. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev. 15 (2001) 1833-1844.
16. Muller, P., Ceskova, P. and Vojtesek, B. Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy. J. Biol. Chem. 280 (2005) 6682-6691.
17. Vojtesek, B., Bartek, J., Midgley, C. A. and Lane, D. P. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods151 (1992) 237-244.
18. Blaydes, J. P. and Hupp, T. R. DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site. Oncogene17 (1998) 1045-1052.
19. Chen, J., Marechal, V. and Levine, A. J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell Biol. 13 (1993) 4107-4114.
20. Sheard, M. A., Krammer, P. H. and Zaloudik, J. Fractionated gamma-irradiation renders tumour cells more responsive to apoptotic signals through CD95. Br. J. Cancer80 (1999) 1689-1696.
21. Sheard, M. A., Vojtesek, B., Janakova, L., Kovarik, J. and Zaloudik, J. Upregulation of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation. Int. J. Cancer73 (1997) 757-762.
22. Wang, D. and Lippard, S. J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4 (2005) 307-320.
23. Siddik, Z. H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene22 (2003) 7265-7279.
24. Kurz, E. U., Douglas, P. and Lees-Miller, S. P. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J. Biol. Chem. 279 (2004) 53272-53281.
25. McHugh, P. J., Spanswick, V. J. and Hartley, J. A. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol. 2 (2001) 483-490.
26. Kartalou, M. and Essigmann, J. M. Recognition of cisplatin adducts by cellular proteins. Mutat. Res. 478 (2001) 1-21.
27. Chaney, S. G., Campbell, S. L., Bassett, E. and Wu, Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev. Oncol. Hematol. 53 (2005) 3-11.
28. Dronkert, M. L. and Kanaar, R. Repair of DNA interstrand cross-links. Mutat. Res. 486 (2001) 217-247.
29. Damia, G., Filiberti, L., Vikhanskaya, F., Carrassa, L., Taya, Y., D'Incalci, M. and Broggini, M. Cisplatinum and taxol induce different patterns of p53 phosphorylation. Neoplasia3 (2001) 10-16.
30. Khanna, K. K., Keating, K. E., Kozlov, S., Scott, S., Gatei, M., Hobson, K., Taya, Y., Gabrielli, B., Chan, D., Lees-Miller, S. P. and Lavin, M. F. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat. Genet. 20 (1998) 398-400.
31. Lakin, N. D., Hann, B. C. and Jackson, S. P. The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53. Oncogene18 (1999) 3989-3995.
32. Tibbetts, R. S., Brumbaugh, K. M., Williams, J. M., Sarkaria, J. N., Cliby, W. A., Shieh, S. Y., Taya, Y., Prives, C. and Abraham, R. T. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 13 (1999) 152-157.
33. Chehab, N. H., Malikzay, A., Appel, M. and Halazonetis, T. D. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev. 14 (2000) 278-288.
34. Chehab, N. H., Malikzay, A., Stavridi, E. S. and Halazonetis, T. D. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13777-13782.
35. Shieh, S. Y., Ikeda, M., Taya, Y. and Prives, C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell91 (1997) 325-334.
36. Delia, D., Fontanella, E., Ferrario, C., Chessa, L. and Mizutani, S. DNA damage-induced cell-cycle phase regulation of p53 and p21waf1 in normal and ATM-defective cells. Oncogene22 (2003) 7866-7869.
37. Hill, R., Bodzak, E., Blough, M. D. and Lee, P. W. p53 Binding to the p21 promoter is dependent on the nature of DNA damage. Cell Cycle7 (2008) 2535-2543.
38. Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M. and Smith, J. R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 211 (1994) 90-98.
39. Lu, Y., Tatsuka, M., Takebe, H. and Yagi, T. Involvement of cyclin-dependent kinases in doxorubicin-induced apoptosis in human tumor cells. Mol. Carcinog. 29 (2000) 1-7.
40. Lu, Y., Yamagishi, N., Yagi, T. and Takebe, H. Mutated p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells. Oncogene16 (1998) 705-712.
41. Luo, Y., Hurwitz, J. and Massague, J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature375 (1995) 159-161.
42. Tang, J. J., Shen, C. and Lu, Y. J. Requirement for pre-existing of p21 to prevent doxorubicin-induced apoptosis through inhibition of caspase-3 activation. Mol. Cell Biochem. 291 (2006) 139-144.
43. Crescenzi, E., Palumbo, G., de Boer, J. and Brady, H. J. Ataxia telangiectasia mutated and p21CIP1 modulate cell survival of drug-induced senescent tumor cells: implications for chemotherapy. Clin. Cancer Res. 14 (2008) 1877-1887.